Catalyst Pharmaceuticals Inc (CPRX)
Return on total capital
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 86,812 | 101,838 | 52,385 | 41,303 | 31,823 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 387,881 | 300,421 | 206,831 | 169,598 | 87,630 |
| Return on total capital | 22.38% | 33.90% | 25.33% | 24.35% | 36.32% |
December 31, 2023 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $86,812K ÷ ($—K + $387,881K)
= 22.38%
Catalyst Pharmaceuticals Inc's return on total capital has exhibited fluctuations over the past five years. The return on total capital was 22.38% in 2023, representing a decline from the previous year's 33.90%. However, the return remained relatively high compared to 2021 and 2020, which were 25.33% and 24.35%, respectively. Notably, the highest return on total capital was recorded in 2019 at 36.32%. This indicates that the company has been able to generate a strong return on the total capital employed in its operations, although there was a recent decrease in 2023 compared to the prior year. Further analysis of the factors contributing to this trend would be necessary to assess the company's overall performance and efficiency in utilizing capital resources.
Peer comparison
Dec 31, 2023